Kingworld Medicines Group Limited (HKG:1110)
Hong Kong
· Delayed Price · Currency is HKD 0.465
0.00 (0.00%)
Apr 29, 2026, 3:58 PM HKT
Kingworld Medicines Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 917.34 | 1,061 | 1,079 | 957.7 | 847.39 | Upgrade
|
| Revenue Growth (YoY) | -13.55% | -1.63% | 12.63% | 13.02% | 13.69% | Upgrade
|
| Cost of Revenue | 669.44 | 790.64 | 797.99 | 680.07 | 583.79 | Upgrade
|
| Gross Profit | 247.91 | 270.45 | 280.67 | 277.63 | 263.6 | Upgrade
|
| Selling, General & Admin | 176.89 | 189.5 | 203.59 | 205.03 | 196.16 | Upgrade
|
| Research & Development | 21.8 | 17.59 | 18.84 | - | - | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | 13.57 | 13.57 | Upgrade
|
| Other Operating Expenses | -7.59 | -30 | -20.88 | -22.35 | -17.42 | Upgrade
|
| Operating Expenses | 191.2 | 177.29 | 201.99 | 197.29 | 192.36 | Upgrade
|
| Operating Income | 56.7 | 93.16 | 78.68 | 80.34 | 71.24 | Upgrade
|
| Interest Expense | -14.05 | -13.28 | -11.52 | -12.29 | -11.78 | Upgrade
|
| Interest & Investment Income | 8.9 | 8.36 | 11.52 | 1.75 | 2.8 | Upgrade
|
| Earnings From Equity Investments | 8.32 | 19.1 | 8.6 | 7.64 | 8.99 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.03 | -10.19 | -4.97 | -5.81 | -3.09 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -2.91 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 58.84 | 94.23 | 82.31 | 71.63 | 68.16 | Upgrade
|
| Gain (Loss) on Sale of Investments | -8.32 | -4.25 | 12.94 | 2.89 | 0.47 | Upgrade
|
| Asset Writedown | 6.84 | 5.16 | -1.36 | -7.3 | 0.8 | Upgrade
|
| Other Unusual Items | 0.07 | 0.37 | - | 0.36 | - | Upgrade
|
| Pretax Income | 57.43 | 95.52 | 93.89 | 67.58 | 69.43 | Upgrade
|
| Income Tax Expense | 18.54 | 21.05 | 32.29 | 24.04 | 18.22 | Upgrade
|
| Earnings From Continuing Operations | 38.89 | 74.47 | 61.59 | 43.54 | 51.21 | Upgrade
|
| Minority Interest in Earnings | -27.61 | -32.91 | -23.5 | -20.8 | -20.89 | Upgrade
|
| Net Income | 11.28 | 41.56 | 38.1 | 22.74 | 30.32 | Upgrade
|
| Net Income to Common | 11.28 | 41.56 | 38.1 | 22.74 | 30.32 | Upgrade
|
| Net Income Growth | -72.85% | 9.09% | 67.52% | -24.99% | 158.78% | Upgrade
|
| Shares Outstanding (Basic) | 586 | 576 | 592 | 607 | 607 | Upgrade
|
| Shares Outstanding (Diluted) | 586 | 576 | 592 | 607 | 607 | Upgrade
|
| Shares Change (YoY) | 1.78% | -2.66% | -2.49% | 0.04% | -1.29% | Upgrade
|
| EPS (Basic) | 0.02 | 0.07 | 0.06 | 0.04 | 0.05 | Upgrade
|
| EPS (Diluted) | 0.02 | 0.07 | 0.06 | 0.04 | 0.05 | Upgrade
|
| EPS Growth | -73.33% | 12.06% | 71.79% | -25.02% | 162.17% | Upgrade
|
| Free Cash Flow | 54.92 | 94.73 | -63.25 | 93.04 | 22.88 | Upgrade
|
| Free Cash Flow Per Share | 0.09 | 0.16 | -0.11 | 0.15 | 0.04 | Upgrade
|
| Dividend Per Share | - | 0.030 | 0.031 | 0.022 | 0.019 | Upgrade
|
| Dividend Growth | - | -2.87% | 40.74% | 11.79% | 254.55% | Upgrade
|
| Gross Margin | 27.02% | 25.49% | 26.02% | 28.99% | 31.11% | Upgrade
|
| Operating Margin | 6.18% | 8.78% | 7.29% | 8.39% | 8.41% | Upgrade
|
| Profit Margin | 1.23% | 3.92% | 3.53% | 2.38% | 3.58% | Upgrade
|
| Free Cash Flow Margin | 5.99% | 8.93% | -5.86% | 9.71% | 2.70% | Upgrade
|
| EBITDA | 72.03 | 104.64 | 88.52 | 107.39 | 96.46 | Upgrade
|
| EBITDA Margin | 7.85% | 9.86% | 8.21% | 11.21% | 11.38% | Upgrade
|
| D&A For EBITDA | 15.33 | 11.49 | 9.84 | 27.05 | 25.22 | Upgrade
|
| EBIT | 56.7 | 93.16 | 78.68 | 80.34 | 71.24 | Upgrade
|
| EBIT Margin | 6.18% | 8.78% | 7.29% | 8.39% | 8.41% | Upgrade
|
| Effective Tax Rate | 32.28% | 22.04% | 34.39% | 35.57% | 26.25% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.